RSSBrief Report

ASPECT-R—A Tool to Rate the Pragmatic and Explanatory Characteristics of a Clinical Trial Design

ASPECT-R—A Tool to Rate the Pragmatic and Explanatory Characteristics of a Clinical Trial Design

| February 1, 2016 | 0 Comments

by Larry D. Alphs, MD, PhD, and Cynthia A. Bossie, PhD Drs. Alphs and Bossie are with Janssen Scientific Affairs, LLC, Titusville, New Jersey, USA. Innov Clin Neurosci. 2016;13(1–2):15–26 Funding: Financial support provided by Janssen Scientific Affairs, LLC. Financial Disclosures: Drs. Alphs and Bossie are full-time employees of Janssen Scientific Affairs, LLC. Key Words: ASPECT-R, […]

Continue Reading

Can Baropodometric Analysis be a Useful Tool in the Early Diagnosis of Atypical Parkinsonism? Preliminary Findings

Can Baropodometric Analysis be a Useful Tool in the Early Diagnosis of Atypical Parkinsonism? Preliminary Findings

| February 3, 2014 | 0 Comments

by Anna Furnari, MD; Rocco Salvatore Calabrò, MD, PhD; Donatella Imbesi, MD, PhD; Francesca La Fauci Belponer, PT; David Militi, PhD; Giuseppe Gervasi, PhD; Concetta Pastura MD, PhD; and Placido Bramanti, MD All from IRCCS Centro Neurolesi “Bonino-Pulejo,” Messina, Italy Innov Clin Neurosci. 2014;11(1–2):23–25

Continue Reading

OPSOCLONUS MYOCLONUS

OPSOCLONUS MYOCLONUS

| December 30, 2011 | 0 Comments

  by Jonathan R. Scarff, MD; Bushra Iftikhar, MD; Aniket Tatugade, MD; Jaekyoung Choi, MD; and Steven Lippmann, MD All from University of Louisville School of Medicine, Department of Psychiatry and Behavioral Sciences, Louisville, Kentucky Innov Clin Neurosci. 2011;8(12):29–31

Continue Reading

Anti-N-methyl-D-aspartate Receptor Encephalitis

Anti-N-methyl-D-aspartate Receptor Encephalitis

| September 30, 2011 | 0 Comments

by Adil Tumbi, MD, MPH; Amin Gilani, MD; Jonathan R. Scarff, MD; Gagandeep Kaur, MD; and Steven Lippmann, MD All from University of Louisville School of Medicine, Psychiatry Department, Louisville, Kentucky Innov Clin Neurosci. 2011;8(9):24–25

Continue Reading

Lisdexamfetamine Dimesylate for the Treatment of Attention Deficit Hyperactivity Disorder in Adults With a History of Depression or History of Substance Use Disorder

Lisdexamfetamine Dimesylate for the Treatment of Attention Deficit Hyperactivity Disorder in Adults With a History of Depression or History of Substance Use Disorder

| February 28, 2011 | 0 Comments

by Scott H. Kollins, PhD; Sharon Youcha, MD; Robert Lasser, MD, MBA; and Michael E. Thase, MD Dr. Kollins is from Duke ADHD Program, Duke University Medical Center, Durham, North Carolina; Drs. Youcha and Lasser are from Shire Development Inc., Wayne, Pennsylvania; and Dr. Thase is from the Department of Psychiatry, University of Pennsylvania School […]

Continue Reading